ema glp-1 vision loss recommendation 2025 Drugs Reduce POAG Risk by Over 50% in Obese Patients This was found at three and five years, along with similar protective effects against ocular hypertension. Specifically, the researchers noted a European Medicines Agency Investigating GLP-1

In recent weeks, Olive Garden, Shake Shack, and Chipotle are among chains that have rolled out special menus with higher-protein, smaller-portioned meals

Vitamin B12 warnings and precautions Patients should always discuss all pre-existing medical conditions, allergies, and medications with their healthcare provider before starting vitamin B12 injections to ensure safety

and absolute changes in HbA1c and patient-reported outcomes (SF-36 Physical Functioning score and IWQoL-Lite-CT Physical Function score) at weeks 48 and 72

A focused clinical assessment is completed

GLP-1 agonists arent magic pills, but they can be powerful tools to remove some of those barriers

North America dominated the market with revenue of USD 1.2 billion in 2025, and is projected to grow at a CAGR of 19.8% through 2034, owing to the presence of a high number of obese and diabetic patients, along with well-developed insurance facilities that promote development of advanced metabolic treatments and regulatory frameworks that make it easier to obtain approval for hormonal combination therapies